메뉴 건너뛰기




Volumn 2011, Issue , 2011, Pages

Monoclonal antibodies in gynecological cancer: A critical point of view

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BEVACIZUMAB; CA 125 ANTIGEN; CAPECITABINE; CARBOPLATIN; CATUMAXOMAB; CD3 ANTIGEN; CETUXIMAB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE; FARLETUZUMAB; FOLATE RECEPTOR; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IPILIMUMAB; MONOCLONAL ANTIBODY; OFATUMUMAB; OREGOVOMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RITUXIMAB; TAXANE DERIVATIVE; TOPOTECAN; TOSITUMOMAB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

EID: 84855593254     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/890758     Document Type: Review
Times cited : (41)

References (126)
  • 1
    • 42949106166 scopus 로고    scopus 로고
    • Monoclonal antibodies in cancer therapy: 25 years of progress
    • Oldham R. K., Dillman R. O., Monoclonal antibodies in cancer therapy: 25 years of progress Journal of Clinical Oncology 2008 26 11 1774 1777
    • (2008) Journal of Clinical Oncology , vol.26 , Issue.11 , pp. 1774-1777
    • Oldham, R.K.1    Dillman, R.O.2
  • 2
    • 0018971622 scopus 로고
    • Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen
    • Nadler L. M., Stashenko P., Hardy R., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen Cancer Research 1980 40 9 3147 3154 (Pubitemid 10043516)
    • (1980) Cancer Research , vol.40 , Issue.9 , pp. 3147-3154
    • Nadler, L.M.1    Stashenko, P.2    Hardy, R.3
  • 4
    • 73349085919 scopus 로고    scopus 로고
    • Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer
    • Spector N. L., Blackwell K. L., Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer Journal of Clinical Oncology 2009 27 34 5838 5847
    • (2009) Journal of Clinical Oncology , vol.27 , Issue.34 , pp. 5838-5847
    • Spector, N.L.1    Blackwell, K.L.2
  • 5
    • 33745738260 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic
    • Ranieri G., Patruno R., Ruggieri E., Montemurro S., Valerio P., Ribatti D., Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic Current Medicinal Chemistry 2006 13 16 1845 1857
    • (2006) Current Medicinal Chemistry , vol.13 , Issue.16 , pp. 1845-1857
    • Ranieri, G.1    Patruno, R.2    Ruggieri, E.3    Montemurro, S.4    Valerio, P.5    Ribatti, D.6
  • 6
    • 77951596808 scopus 로고    scopus 로고
    • Catumaxomab: Clinical development and future directions
    • Linke R., Klein A., Seimetz D., Catumaxomab: clinical development and future directions mAbs 2010 2 2 129 136
    • (2010) MAbs , vol.2 , Issue.2 , pp. 129-136
    • Linke, R.1    Klein, A.2    Seimetz, D.3
  • 7
    • 0030923795 scopus 로고    scopus 로고
    • Vascular endothelial growth factor expression in early stage ovarian carcinoma
    • DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A
    • Paley P. J., Staskus K. A., Gebhard K., Mohanraj D., Twiggs L. B., Carson L. F., Ramakrishnan S., Vascular endothelial growth factor expression in early stage ovarian carcinoma Cancer 1997 80 1 98 106 (Pubitemid 27270925)
    • (1997) Cancer , vol.80 , Issue.1 , pp. 98-106
    • Paley, P.J.1    Staskus, K.A.2    Gebhard, K.3    Mohanraj, D.4    Twiggs, L.B.5    Carson, L.F.6    Ramakrishnan, S.7
  • 8
    • 1842850792 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients
    • DOI 10.1016/j.clinbiochem.2004.01.014, PII S0009912004000281
    • Kassim S. K., El-Salahy E. M., Fayed S. T., Helal S. A., Helal T., Azzam E. E. D., Khalifa A., Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients Clinical Biochemistry 2004 37 5 363 369 (Pubitemid 38490454)
    • (2004) Clinical Biochemistry , vol.37 , Issue.5 , pp. 363-369
    • Kassim, S.K.1    El-Salahy, E.M.2    Fayed, S.T.3    Helal, S.A.4    Helal, T.5    Azzam, E.E.-D.6    Khalifa, A.7
  • 11
    • 33751006991 scopus 로고    scopus 로고
    • Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer
    • DOI 10.1016/j.ygyno.2006.03.058, PII S0090825806002903
    • Hefler L. A., Zeillinger R., Grimm C., Sood A. K., Cheng W. F., Gadducci A., Tempfer C. B., Reinthaller A., Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecologic Oncology 2006 103 2 512 517 (Pubitemid 44740099)
    • (2006) Gynecologic Oncology , vol.103 , Issue.2 , pp. 512-517
    • Hefler, L.A.1    Zeillinger, R.2    Grimm, C.3    Sood, A.K.4    Cheng, W.F.5    Gadducci, A.6    Tempfer, C.B.7    Reinthaller, A.8
  • 14
    • 0034796595 scopus 로고    scopus 로고
    • Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
    • DOI 10.1038/nm0901-987
    • Jain R. K., Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nature Medicine 2001 7 9 987 989 (Pubitemid 32937367)
    • (2001) Nature Medicine , vol.7 , Issue.9 , pp. 987-989
    • Jain, R.K.1
  • 15
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • DOI 10.1126/science.1104819
    • Jain R. K., Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 2005 307 5706 58 62 (Pubitemid 40093472)
    • (2005) Science , vol.307 , Issue.5706 , pp. 58-62
    • Jain, R.K.1
  • 16
    • 79957902010 scopus 로고    scopus 로고
    • Signal transduction by vascular endothelial growth factor receptors
    • Koch S., Tugues S., Li X., Signal transduction by vascular endothelial growth factor receptors Biochemical Journal 2011 437 2 169 183
    • (2011) Biochemical Journal , vol.437 , Issue.2 , pp. 169-183
    • Koch, S.1    Tugues, S.2    Li, X.3
  • 21
    • 13844266766 scopus 로고    scopus 로고
    • Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
    • DOI 10.1016/j.ygyno.2004.12.001
    • Monk B. J., Choi D. C., Pugmire G., Burger R. A., Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer Gynecologic Oncology 2005 96 3 902 905 (Pubitemid 40255525)
    • (2005) Gynecologic Oncology , vol.96 , Issue.3 , pp. 902-905
    • Monk, B.J.1    Choi, D.C.2    Pugmire, G.3    Burger, R.A.4
  • 22
    • 33745308428 scopus 로고    scopus 로고
    • Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis
    • DOI 10.1002/cncr.21969
    • Wright J. D., Hagemann A., Rader J. S., Viviano D., Gibb R. K., Norris L., Mutch D. G., Powell M. A., Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis Cancer 2006 107 1 83 89 (Pubitemid 43939034)
    • (2006) Cancer , vol.107 , Issue.1 , pp. 83-89
    • Wright, J.D.1    Hagemann, A.2    Rader, J.S.3    Viviano, D.4    Gibb, R.K.5    Norris, L.6    Mutch, D.G.7    Powell, M.A.8
  • 23
    • 33745875210 scopus 로고    scopus 로고
    • Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer
    • DOI 10.1016/j.ygyno.2006.01.030, PII S009082580600059X
    • Cohn D. E., Valmadre S., Resnick K. E., Eaton L. A., Copeland L. J., Fowler J. M., Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer Gynecologic Oncology 2006 102 2 134 139 (Pubitemid 44056263)
    • (2006) Gynecologic Oncology , vol.102 , Issue.2 , pp. 134-139
    • Cohn, D.E.1    Valmadre, S.2    Resnick, K.E.3    Eaton, L.A.4    Copeland, L.J.5    Fowler, J.M.6
  • 24
    • 36849019301 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study
    • Burger R. A., Sill M. W., Monk B. J., Greer B. E., Sorosky J. I., Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study Journal of Clinical Oncology 2007 25 33 5165 5167
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.33 , pp. 5165-5167
    • Burger, R.A.1    Sill, M.W.2    Monk, B.J.3    Greer, B.E.4    Sorosky, J.I.5
  • 25
    • 35348904080 scopus 로고    scopus 로고
    • Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    • DOI 10.1016/j.ygyno.2007.07.017, PII S0090825807004635
    • Chura J. C., van Iseghem K., Downs L. S. Jr, Carson L. F., Judson P. L., Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer Gynecologic Oncology 2007 107 2 326 330 (Pubitemid 47575735)
    • (2007) Gynecologic Oncology , vol.107 , Issue.2 , pp. 326-330
    • Chura, J.C.1    Van Iseghem, K.2    Downs Jr., L.S.3    Carson, L.F.4    Judson, P.L.5
  • 26
    • 34648829056 scopus 로고    scopus 로고
    • Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening
    • DOI 10.1016/j.ygyno.2007.06.004, PII S0090825807004179
    • Simpkins F., Belinson J. L., Rose P. G., Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening Gynecologic Oncology 2007 107 1 118 123 (Pubitemid 47464553)
    • (2007) Gynecologic Oncology , vol.107 , Issue.1 , pp. 118-123
    • Simpkins, F.1    Belinson, J.L.2    Rose, P.G.3
  • 29
    • 45549099056 scopus 로고    scopus 로고
    • Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
    • Nimeiri H. S., Oza A. M., Morgan R. J., Friberg G., Kasza K., Faoro L., Salgia R., Stadler W. M., Vokes E. E., Fleming G. F., Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II consortia Gynecologic Oncology 2008 110 1 49 55
    • (2008) Gynecologic Oncology , vol.110 , Issue.1 , pp. 49-55
    • Nimeiri, H.S.1    Oza, A.M.2    Morgan, R.J.3    Friberg, G.4    Kasza, K.5    Faoro, L.6    Salgia, R.7    Stadler, W.M.8    Vokes, E.E.9    Fleming, G.F.10
  • 31
    • 33748475636 scopus 로고    scopus 로고
    • The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma
    • DOI 10.1016/j.ygyno.2006.05.018, PII S0090825806004306
    • Numnum T. M., Rocconi R. P., Whitworth J., Barnes M. N., The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma Gynecologic Oncology 2006 102 3 425 428 (Pubitemid 44353660)
    • (2006) Gynecologic Oncology , vol.102 , Issue.3 , pp. 425-428
    • Numnum, T.M.1    Rocconi, R.P.2    Whitworth, J.3    Barnes, M.N.4
  • 34
    • 56449083159 scopus 로고    scopus 로고
    • The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: A case report
    • Kesterson J. P., Mhawech-Fauceglia P., Lele S., The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report Gynecologic Oncology 2008 111 3 527 529
    • (2008) Gynecologic Oncology , vol.111 , Issue.3 , pp. 527-529
    • Kesterson, J.P.1    Mhawech-Fauceglia, P.2    Lele, S.3
  • 35
    • 78549259164 scopus 로고    scopus 로고
    • Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review
    • Bellati F., Napoletano C., Ruscito I., Pastore M., Pernice M., Antonilli M., Nuti M., Benedetti Panici P., Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review Investigational New Drugs 2010 28 6 887 894
    • (2010) Investigational New Drugs , vol.28 , Issue.6 , pp. 887-894
    • Bellati, F.1    Napoletano, C.2    Ruscito, I.3    Pastore, M.4    Pernice, M.5    Antonilli, M.6    Nuti, M.7    Benedetti Panici, P.8
  • 37
    • 84855605968 scopus 로고    scopus 로고
    • ID protocol number: NCT00262847
    • http://www.cancer.gov/ (ID protocol number: NCT00262847)
  • 38
    • 84855600478 scopus 로고    scopus 로고
    • (ID protocol number: NCT00483782)
    • http://www.cancer.gov/ (ID protocol number: NCT00483782)
  • 39
    • 84855600479 scopus 로고    scopus 로고
    • (ID protocol number: NCT00976911)
    • http://www.cancer.gov/ (ID protocol number: NCT00976911)
  • 40
    • 84855578023 scopus 로고    scopus 로고
    • (ID protocol number: NCT00565851)
    • http://www.cancer.gov/ (ID protocol number: NCT00565851)
  • 41
    • 84855600477 scopus 로고    scopus 로고
    • (ID protocol number: NCT00434642)
    • http://www.cancer.gov (ID protocol number: NCT00434642)
  • 42
    • 0041629450 scopus 로고    scopus 로고
    • Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
    • DOI 10.1200/JCO.2003.01.504
    • Mendelsohn J., Baselga J., Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer Journal of Clinical Oncology 2003 21 14 2787 2799 (Pubitemid 46606324)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.14 , pp. 2787-2799
    • Mendelsohn, J.1    Baselga, J.2
  • 43
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon D. J., Clark G. M., Wong S. G., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987 235 4785 177 182 (Pubitemid 17231334)
    • (1987) Science , vol.235 , Issue.4785 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 45
    • 28444443755 scopus 로고    scopus 로고
    • Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma
    • DOI 10.1093/annonc/mdi405
    • Delord J. P., Allal C., Canal M., Mery E., Rochaix P., Hennebelle I., Pradines A., Chatelut E., Bugat R., Guichard S., Canal P., Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma Annals of Oncology 2005 16 12 1889 1897 (Pubitemid 41724277)
    • (2005) Annals of Oncology , vol.16 , Issue.12 , pp. 1889-1897
    • Delord, J.P.1    Allal, C.2    Canal, M.3    Mery, E.4    Rochaix, P.5    Hennebelle, I.6    Pradines, A.7    Chatelut, E.8    Bugat, R.9    Guichard, S.10    Canal, P.11
  • 46
    • 0036869728 scopus 로고    scopus 로고
    • HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: Possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab
    • Fujimura M., Katsumata N., Tsuda H., Uchi N., Miyazaki S., Hidaka T., Sakai M., Saito S., HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab Japanese Journal of Cancer Research 2002 93 11 1250 1257 (Pubitemid 36032989)
    • (2002) Japanese Journal of Cancer Research , vol.93 , Issue.11 , pp. 1250-1257
    • Fujimura, M.1    Katsumata, N.2    Tsuda, H.3    Uchi, N.4    Miyazaki, S.5    Hidaka, T.6    Sakai, M.7    Saito, S.8
  • 50
    • 0037440042 scopus 로고    scopus 로고
    • Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
    • DOI 10.1200/JCO.2003.10.104
    • Bookman M. A., Darcy K. M., Clarke-Pearson D., Boothby R. A., Horowitz I. R., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group Journal of Clinical Oncology 2003 21 2 283 290 (Pubitemid 46606157)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.2 , pp. 283-290
    • Bookman, M.A.1    Darcy, K.M.2    Clarke-Pearson, D.3    Boothby, R.A.4    Horowitz, I.R.5
  • 51
    • 1842605531 scopus 로고    scopus 로고
    • Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
    • DOI 10.1016/S1535-6108(04)00083-2, PII S1535610804000832
    • Franklin M. C., Carey K. D., Vajdos F. F., Leahy D. J., de Vos A. M., Sliwkowski M. X., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 2004 5 4 317 328 (Pubitemid 38482068)
    • (2004) Cancer Cell , vol.5 , Issue.4 , pp. 317-328
    • Franklin, M.C.1    Carey, K.D.2    Vajdos, F.F.3    Leahy, D.J.4    De Vos, A.M.5    Sliwkowski, M.X.6
  • 52
    • 0035874981 scopus 로고    scopus 로고
    • Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells
    • Molina M. A., Codony-Servat J., Albanell J., Rojo F., Arribas J., Baselga J., Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells Cancer Research 2001 61 12 4744 4749 (Pubitemid 32691885)
    • (2001) Cancer Research , vol.61 , Issue.12 , pp. 4744-4749
    • Molina, M.A.1    Codony-Servat, J.2    Albanell, J.3    Rojo, F.4    Arribas, J.5    Baselga, J.6
  • 55
    • 0030054907 scopus 로고    scopus 로고
    • Anti-tremor and cell cycle responses in KB celIs treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin
    • Prewett M., Rockwell P., Rose C., Goldstein N. I., Anti-tremor and cell cycle responses in KB celIs treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin International Journal of Oncology 1996 9 2 217 224 (Pubitemid 26236011)
    • (1996) International Journal of Oncology , vol.9 , Issue.2 , pp. 217-224
    • Prewett, M.1    Rockwell, P.2    Rose, C.3    Goldstein, N.I.4
  • 56
    • 39249085402 scopus 로고    scopus 로고
    • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: A gynecologic oncology group study
    • Secord A. A., Blessing J. A., Armstrong D. K., Rodgers W. H., Miner Z., Barnes M. N., Lewandowski G., Mannel R. S., Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a gynecologic oncology group study Gynecologic Oncology 2008 108 493 499
    • (2008) Gynecologic Oncology , vol.108 , pp. 493-499
    • Secord, A.A.1    Blessing, J.A.2    Armstrong, D.K.3    Rodgers, W.H.4    Miner, Z.5    Barnes, M.N.6    Lewandowski, G.7    Mannel, R.S.8
  • 57
    • 0027428571 scopus 로고
    • Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
    • Fan Z., Baselga J., Masui H., Mendelsohn J., Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts Cancer Research 1993 53 19 4637 4642 (Pubitemid 23304392)
    • (1993) Cancer Research , vol.53 , Issue.18 , pp. 4637-4642
    • Fan, Z.1    Baselga, J.2    Masui, H.3    Mendelsohn, J.4
  • 58
    • 0028819660 scopus 로고
    • Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
    • Goldstein N. I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J., Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clinical Cancer Research 1995 1 11 1311 1318
    • (1995) Clinical Cancer Research , vol.1 , Issue.11 , pp. 1311-1318
    • Goldstein, N.I.1    Prewett, M.2    Zuklys, K.3    Rockwell, P.4    Mendelsohn, J.5
  • 59
    • 16244371388 scopus 로고    scopus 로고
    • Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells
    • New Anticancer Agents
    • Sung F. L., Poon T. C., Hui E. P., Ma B. B. Y., Liong E., To K. F., Huang D. P. W. S., Chan A. T. C., Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells In Vivo 2005 19 1 237 246 (Pubitemid 40450402)
    • (2005) Vivo , vol.19 , Issue.1 , pp. 237-246
    • Sung, F.L.1    Poon, T.C.W.2    Hui, E.P.3    Ma, B.B.Y.4    Liong, E.5    To, K.F.6    Huang, D.P.W.S.7    Chan, A.T.C.8
  • 61
    • 47249145102 scopus 로고    scopus 로고
    • A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer
    • Konner J., Schilder R. J., DeRosa F. A., Gerst S. R., Tew W. P., Sabbatini P. J., Hensley M. L., Spriggs D. R., Aghajanian C. A., A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer Gynecologic Oncology 2008 110 2 140 145
    • (2008) Gynecologic Oncology , vol.110 , Issue.2 , pp. 140-145
    • Konner, J.1    Schilder, R.J.2    Derosa, F.A.3    Gerst, S.R.4    Tew, W.P.5    Sabbatini, P.J.6    Hensley, M.L.7    Spriggs, D.R.8    Aghajanian, C.A.9
  • 62
    • 70349745159 scopus 로고    scopus 로고
    • A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: A gynecologic oncology group study
    • Fiorica J. V., Blessing J. A., Puneky L. V., Secord A. A., Hoffman J. S., Yamada S. D., Buekers T. E., Bell J., Schilder J. M., A Phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a gynecologic oncology group study Gynecologic Oncology 2009 115 2 285 289
    • (2009) Gynecologic Oncology , vol.115 , Issue.2 , pp. 285-289
    • Fiorica, J.V.1    Blessing, J.A.2    Puneky, L.V.3    Secord, A.A.4    Hoffman, J.S.5    Yamada, S.D.6    Buekers, T.E.7    Bell, J.8    Schilder, J.M.9
  • 64
    • 0034051390 scopus 로고    scopus 로고
    • The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells
    • Zeidler R., Mysliwietz J., Csnady M., Walz A., Ziegler I., Schmitt B., Wollenberg B., Lindhofer H., The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells British Journal of Cancer 2000 83 2 261 266 (Pubitemid 30411727)
    • (2000) British Journal of Cancer , vol.83 , Issue.2 , pp. 261-266
    • Zeidler, R.1    Mysliwietz, J.2    Csanady, M.3    Walz, A.4    Ziegler, I.5    Schmitt, B.6    Wollenberg, B.7    Lindhofer, H.8
  • 68
    • 36849091953 scopus 로고    scopus 로고
    • MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer
    • Kalli K. R., MORAb-003, a fully humanized monoclonal antibody against the folate receptor, for the potential treatment of epithelial ovarian cancer Current Opinion in Investigational Drugs 2007 8 12 1067 1073 (Pubitemid 350224332)
    • (2007) Current Opinion in Investigational Drugs , vol.8 , Issue.12 , pp. 1067-1073
    • Kalli, K.R.1
  • 71
    • 0020559574 scopus 로고
    • A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
    • Bast R. C. Jr, Klug T. L., St John E., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer New England Journal of Medicine 1983 309 15 883 887 (Pubitemid 13014028)
    • (1983) New England Journal of Medicine , vol.309 , Issue.15 , pp. 883-887
    • Bast Jr., R.C.1    Klug, T.L.2    St. John, E.3
  • 73
    • 0035886979 scopus 로고    scopus 로고
    • Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels
    • Rustin G. J., Marples M., Nelstrop A. E., Mahmoudi M., Meyer T., Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels Journal of Clinical Oncology 2001 19 20 4054 4057 (Pubitemid 32976692)
    • (2001) Journal of Clinical Oncology , vol.19 , Issue.20 , pp. 4054-4057
    • Rustin, G.J.S.1    Marples, M.2    Nelstrop, A.E.3    Mahmoudi, M.4    Meyer, T.5
  • 77
    • 0034947607 scopus 로고    scopus 로고
    • Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13 - Evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo
    • Noujaim A. A., Schultes B. C., Baum R. P., Madiyalakan R., Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo Cancer Biotherapy and Radiopharmaceuticals 2001 16 3 187 203 (Pubitemid 32641217)
    • (2001) Cancer Biotherapy and Radiopharmaceuticals , vol.16 , Issue.3 , pp. 187-203
    • Noujaim, A.A.1    Schultes, B.C.2    Baum, R.P.3    Madiyalakan, R.4
  • 78
    • 3142670929 scopus 로고    scopus 로고
    • CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients
    • DOI 10.1016/j.ygyno.2004.04.024, PII S0090825804002781
    • Gordon A. N., Schultes B. C., Gallion H., Edwards R., Whiteside T. L., Cermak J. M., Nicodemus C. F., CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients Gynecologic Oncology 2004 94 2 340 351 (Pubitemid 39024536)
    • (2004) Gynecologic Oncology , vol.94 , Issue.2 , pp. 340-351
    • Gordon, A.N.1    Schultes, B.C.2    Gallion, H.3    Edwards, R.4    Whiteside, T.L.5    Cermak, J.M.6    Nicodemus, C.F.7
  • 80
    • 14244250598 scopus 로고    scopus 로고
    • A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
    • DOI 10.1111/j.1525-1438.2005.00483.x
    • Ehlen T. G., Hoskins P. J., Miller D., Whiteside T. L., Nicodemus C. F., Schultes B. C., Swenerton K. D., A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer International Journal of Gynecological Cancer 2005 15 6 1023 1034 (Pubitemid 43110150)
    • (2005) International Journal of Gynecological Cancer , vol.15 , Issue.6 , pp. 1023-1034
    • Ehlen, T.G.1    Hoskins, P.J.2    Miller, D.3    Whiteside, T.L.4    Nicodemus, C.F.5    Schultes, B.C.6    Swenerton, K.D.7
  • 81
    • 44949115169 scopus 로고    scopus 로고
    • CA125 velocity at relapse is a highly significant predictor of survival post relapse: Results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer
    • Berek J. S., Taylor P. T., Nicodemus C. F., CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer Journal of Immunotherapy 2008 31 2 207 214
    • (2008) Journal of Immunotherapy , vol.31 , Issue.2 , pp. 207-214
    • Berek, J.S.1    Taylor, P.T.2    Nicodemus, C.F.3
  • 83
    • 33748101092 scopus 로고    scopus 로고
    • MUC1 cytoplasmic tail: A potential therapeutic target for ovarian carcinoma
    • DOI 10.1586/14737140.6.8.1261
    • Hu X. F., Yang E., Li J., Xing P. X., MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma Expert Review of Anticancer Therapy 2006 6 8 1261 1271 (Pubitemid 44304694)
    • (2006) Expert Review of Anticancer Therapy , vol.6 , Issue.8 , pp. 1261-1271
    • Hu, X.F.1    Yang, E.2    Li, J.3    Xing, P.X.4
  • 84
    • 0035370711 scopus 로고    scopus 로고
    • The importance of MUC1 cellular localization in patients with breast carcinoma: An immunohistologic study of 71 patients and review of the literature
    • DOI 10.1002/1097-0142(20010601)91:11<1973::AID-CNCR1222>3.0.CO;2-A
    • Rahn J. J., Dabbagh L., Pasdar M., Hugh J. C., The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature Cancer 2001 91 11 1973 1982 (Pubitemid 32476360)
    • (2001) Cancer , vol.91 , Issue.11 , pp. 1973-1982
    • Rahn, J.J.1    Dabbagh, L.2    Pasdar, M.3    Hugh, J.C.4
  • 85
    • 0030070154 scopus 로고    scopus 로고
    • The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells
    • DOI 10.1074/jbc.271.4.2332
    • Pemberton L. F., Rughetti A., Taylor-Papadimitriou J., Gendler S. J., The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells Journal of Biological Chemistry 1996 271 4 2332 2340 (Pubitemid 26047827)
    • (1996) Journal of Biological Chemistry , vol.271 , Issue.4 , pp. 2332-2340
    • Pemberton, L.F.1    Rughetti, A.2    Taylor-Papadimitriou, J.3    Gendler, S.J.4
  • 89
    • 0031985010 scopus 로고    scopus 로고
    • Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: A matched analysis
    • Maraveyas A., Mason P., Lambert H. E., Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis Oncology Reports 2001 5 1 223 226
    • (2001) Oncology Reports , vol.5 , Issue.1 , pp. 223-226
    • Maraveyas, A.1    Mason, P.2    Lambert, H.E.3
  • 90
    • 0034004410 scopus 로고    scopus 로고
    • Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy
    • DOI 10.1046/j.1525-1438.2000.99510.x
    • Epenetos A. A., Hird V., Lambert H., Mason P., Coulter C., Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy International Journal of Gynecological Cancer 2000 10 1 44 46 (Pubitemid 30220628)
    • (2000) International Journal of Gynecological Cancer , vol.10 , Issue.SUPPL. 1 , pp. 44-46
    • Epenetos, A.A.1    Hird, V.2    Lambert, H.3    Mason, P.4    Coulter, C.5
  • 95
    • 84855578032 scopus 로고    scopus 로고
    • http://www.antisoma.com/
  • 100
    • 0033899157 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF) expression is a prognostic faster for radiotherapy outcome in advanced carcinoma of the cervix
    • Loncaster J. A., Cooper R. A., Logue J. P., Davidson S. E., Hunter R. D., West C. M. L., Vascular endothelial growth factor (VEGF) expression is a prognostic faster for radiotherapy outcome in advanced carcinoma of the cervix British Journal of Cancer 2000 83 5 620 625 (Pubitemid 30636303)
    • (2000) British Journal of Cancer , vol.83 , Issue.5 , pp. 620-625
    • Loncaster, J.A.1    Cooper, R.A.2    Logue, J.P.3    Davidson, S.E.4    Hunter, R.D.5    West, C.M.L.6
  • 101
    • 61549141361 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A gynecologic oncology group study
    • Monk B. J., Sill M. W., Burger R. A., Gray H. J., Buekers T. E., Roman L. D., Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study Journal of Clinical Oncology 2009 27 7 1069 1074
    • (2009) Journal of Clinical Oncology , vol.27 , Issue.7 , pp. 1069-1074
    • Monk, B.J.1    Sill, M.W.2    Burger, R.A.3    Gray, H.J.4    Buekers, T.E.5    Roman, L.D.6
  • 102
    • 33745308428 scopus 로고    scopus 로고
    • Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis
    • DOI 10.1002/cncr.21969
    • Wright J. D., Hagemann A., Rader J. S., Viviano D., Gibb R. K., Norris L., Mutch D. G., Powell M. A., Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis Cancer 2006 107 1 83 89 (Pubitemid 43939034)
    • (2006) Cancer , vol.107 , Issue.1 , pp. 83-89
    • Wright, J.D.1    Hagemann, A.2    Rader, J.S.3    Viviano, D.4    Gibb, R.K.5    Norris, L.6    Mutch, D.G.7    Powell, M.A.8
  • 103
    • 84855583549 scopus 로고    scopus 로고
    • (ID protocol number: NCT00803062)
    • http://www.cancer.gov/ (ID protocol number: NCT00803062)
  • 104
    • 80052560749 scopus 로고    scopus 로고
    • Is there a real standard for stage Iva cervical cancer?
    • Bellati F., Gasparri M. L., Panici P. B., Is there a real standard for stage Iva cervical cancer? Gynecologic Oncology 2011 123 1 174 175
    • (2011) Gynecologic Oncology , vol.123 , Issue.1 , pp. 174-175
    • Bellati, F.1    Gasparri, M.L.2    Panici, P.B.3
  • 108
    • 0033042754 scopus 로고    scopus 로고
    • Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis
    • Kersemaekers A. M., Fleuren G. J., Kenter G. G., van den Broek L. J. C. M., Uljee S. M., Hermans J., van de Vijver M. J., Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis Clinical Cancer Research 1999 5 3 577 586 (Pubitemid 29131967)
    • (1999) Clinical Cancer Research , vol.5 , Issue.3 , pp. 577-586
    • Kersemaekers, A.-M.F.1    Fleuren, G.J.2    Kenter, G.G.3    Van Den Broek, L.J.C.M.4    Uljee, S.M.5    Hermans, J.6    Van De Vijver, M.J.7
  • 109
    • 12144290754 scopus 로고    scopus 로고
    • Synchronous Coexpression of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in Carcinomas of the Uterine Cervix: A Potential Predictor of Poor Survival
    • DOI 10.1158/1078-0432.CCR-0497-03
    • Kim G. E., Kim Y. B., Cho N. H., Chung H. C., Pyo H. R., Lee J. D., Park T. K., Koom W. S., Chun M., Suh C. O., Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival Clinical Cancer Research 2004 10 4 1366 1374 (Pubitemid 38365230)
    • (2004) Clinical Cancer Research , vol.10 , Issue.4 , pp. 1366-1374
    • Kim, G.E.1    Kim, Y.B.2    Cho, N.H.3    Chung, H.-C.4    Pyo, H.R.5    Lee, J.D.6    Park, T.K.7    Koom, W.S.8    Chun, M.9    Suh, C.O.10
  • 111
    • 0024599422 scopus 로고
    • Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix
    • DOI 10.1016/0090-8258(89)90540-4
    • Pfeiffer D., Stellwag B., Pfeiffer A., Borlinghaus P., Mjeier W., Scheidel P., Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix Gynecologic Oncology 1989 33 2 146 150 (Pubitemid 19112903)
    • (1989) Gynecologic Oncology , vol.33 , Issue.2 , pp. 146-150
    • Pfeiffer, D.1    Stellwag, B.2    Pfeiffer, A.3    Borlinghaus, P.4    Mjeier, W.5    Scheidel, P.6
  • 112
    • 34548124985 scopus 로고    scopus 로고
    • Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
    • DOI 10.1016/j.ygyno.2007.04.028, PII S0090825807003022
    • Bellone J., Norton L., Masui H., Romani C., Bandiera E., Tognon G., Roman J. J., Burnett A. F., Pecorelli S., Santin A. D., Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease Gynecologic Oncology 2007 106 3 513 520 (Pubitemid 47302461)
    • (2007) Gynecologic Oncology , vol.106 , Issue.3 , pp. 513-520
    • Bellone, S.1    Frera, G.2    Landolfi, G.3    Romani, C.4    Bandiera, E.5    Tognon, G.6    Roman, J.J.7    Burnett, A.F.8    Pecorelli, S.9    Santin, A.D.10
  • 114
    • 34548124985 scopus 로고    scopus 로고
    • Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
    • DOI 10.1016/j.ygyno.2007.04.028, PII S0090825807003022
    • Bellone S., Frera G., Landolfi G., Romani C., Bandiera E., Tognon G., Roman J. J., Burnett A. F., Pecorelli S., Santin A. D., Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease Gynecologic Oncology 2007 106 3 513 520 (Pubitemid 47302461)
    • (2007) Gynecologic Oncology , vol.106 , Issue.3 , pp. 513-520
    • Bellone, S.1    Frera, G.2    Landolfi, G.3    Romani, C.4    Bandiera, E.5    Tognon, G.6    Roman, J.J.7    Burnett, A.F.8    Pecorelli, S.9    Santin, A.D.10
  • 116
    • 80051551247 scopus 로고    scopus 로고
    • Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A gynecologic oncology group study
    • Santin A. D., Sill M. W., McMeekin D. S., Leitao M. M., Brown J., Sutton G. P., van Le L., Griffin P., Boardman C. H., Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study Gynecologic Oncology 2011 122 3 495 500
    • (2011) Gynecologic Oncology , vol.122 , Issue.3 , pp. 495-500
    • Santin, A.D.1    Sill, M.W.2    McMeekin, D.S.3    Leitao, M.M.4    Brown, J.5    Sutton, G.P.6    Van Le, L.7    Griffin, P.8    Boardman, C.H.9
  • 119
    • 79955481029 scopus 로고    scopus 로고
    • Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A gynecologic oncology group study
    • Farley J., Sill M. W., Birrer M., Walker J., Schilder R. J., Thigpen J. T., Coleman R. L., Miller B. E., Rose P. G., Lankes H. A., Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a gynecologic oncology group study Gynecologic Oncology 2011 121 2 303 308
    • (2011) Gynecologic Oncology , vol.121 , Issue.2 , pp. 303-308
    • Farley, J.1    Sill, M.W.2    Birrer, M.3    Walker, J.4    Schilder, R.J.5    Thigpen, J.T.6    Coleman, R.L.7    Miller, B.E.8    Rose, P.G.9    Lankes, H.A.10
  • 120
    • 68749085025 scopus 로고    scopus 로고
    • A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A gynecologic oncology group (GOG) studyASCO
    • Aghajanian C., Sill M. W., Darcy K., A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: a gynecologic oncology group (GOG) studyASCO Journal of Clinical Oncology 2009 27 15s
    • (2009) Journal of Clinical Oncology , vol.27
    • Aghajanian, C.1    Sill, M.W.2    Darcy, K.3
  • 121
    • 35348985425 scopus 로고    scopus 로고
    • Bevacizumab therapy in patients with recurrent uterine neoplasms
    • Wright J. D., Powell M. A., Rader J. S., Mutch D. G., Gibb R. K., Bevacizumab therapy in patients with recurrent uterine neoplasms Anticancer Research 2007 27 5 3525 3528 (Pubitemid 47607497)
    • (2007) Anticancer Research , vol.27 , Issue.B5 , pp. 3525-3528
    • Wright, J.D.1    Powell, M.A.2    Rader, J.S.3    Mutch, D.G.4    Gibb, R.K.5
  • 122
    • 70349878651 scopus 로고    scopus 로고
    • Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
    • Katsumata N., Yasuda M., Takahashi F., Isonishi S., Jobo T., Aoki D., Tsuda H., Sugiyama T., Kodama S., Kimura E., Ochiai K., Noda K., Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial The Lancet 2009 374 9698 1331 1338
    • (2009) The Lancet , vol.374 , Issue.9698 , pp. 1331-1338
    • Katsumata, N.1    Yasuda, M.2    Takahashi, F.3    Isonishi, S.4    Jobo, T.5    Aoki, D.6    Tsuda, H.7    Sugiyama, T.8    Kodama, S.9    Kimura, E.10    Ochiai, K.11    Noda, K.12
  • 124
    • 83055173012 scopus 로고    scopus 로고
    • Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    • In press
    • Markman M., Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecologic Oncology. In press
    • Gynecologic Oncology
    • Markman, M.1
  • 125
    • 8344227715 scopus 로고    scopus 로고
    • Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?
    • DOI 10.1097/00001813-200410000-00007
    • Lau D., Guo L., Gandara D., Young L. J. T., Xue L., Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent? Anti-Cancer Drugs 2004 15 9 871 875 (Pubitemid 39482927)
    • (2004) Anti-Cancer Drugs , vol.15 , Issue.9 , pp. 871-875
    • Lau, D.1    Guo, L.2    Gandara, D.3    Young, L.J.T.4    Xue, L.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.